Department of Pathology and Laboratory Medicine, Weill Cornell Medical College/New York Presbyterian Hospital, New York, NY, USA.
Hematopathology Service, Division of Pathology, Department of Pathophysiology and Transplantation, University of Milan and IRCCS Ca' Granda - Ospedale Maggiore Policlinico Foundation, Milan, Italy.
Mod Pathol. 2015 Nov;28(11):1448-57. doi: 10.1038/modpathol.2015.100. Epub 2015 Sep 4.
Polycythemia vera in 20-30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥ 13 × 10⁹/l (median: 25.1 × 10⁹/l; range: 16.1-89.7 × 10⁹/l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥ 10% immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.
真性红细胞增多症在 20-30%的病例中会进展为后红细胞增多性骨髓纤维化,这是一个晚期阶段,其特征是红细胞计数减少,脾脏肿大并出现髓外造血。有证据表明,真性红细胞增多症发病时中性粒细胞白细胞增多与复发性血栓形成的风险增加有关。然而,其在疾病过程中后来发展的临床意义尚不清楚。在 8 年的时间里,我们从两个参考中心的档案中确定了 10 名患者(7 名男性/3 名女性,中位年龄:68 岁),他们在诊断后红细胞增多性骨髓纤维化时或前后出现持续的绝对白细胞增多症≥13×10⁹/l(中位数:25.1×10⁹/l;范围:16.1-89.7×10⁹/l)(中位数间隔:0 个月;范围:-6/31),并持续了中位时间 13 个月。外周血涂片显示大量无发育异常特征的中性粒细胞,其中 4 例患者有≥10%的不成熟髓系前体。在 5 例病例中,在白细胞增多症发作时或之后立即获得的相应骨髓标本显示由于粒细胞增殖而骨髓有核细胞:红细胞比值显著增加。白细胞增多症的发生与 JAK2 和 BCR-ABL1 状态或细胞遗传学演变无关。CSF3R、SETBP1 和 SRSF2 基因的突变状态与其他发生中性粒细胞白细胞增多症的慢性髓系肿瘤有关,但所有病例均仅显示野生型等位基因。4 名患者在发生白细胞增多症后死亡,1 名患者病情恶化。与从未发生持续白细胞增多症的后红细胞增多性骨髓纤维化患者对照组(n=23)相比,白细胞增多症患者的白细胞计数更高,总生存期更短。这是第一项描述真性红细胞增多症晚期出现显著中性粒细胞白细胞增多症的研究;它包括全面的血液学、骨髓形态学、分子和临床数据。我们的发现表明,在进展为后红细胞增多性骨髓纤维化时或前后出现的持续性白细胞增多症与疾病的总体侵袭性更强有关。